000			03987nam a22006257a 4500
008			190314s20192019 xxu||||| |||| 00| 0 eng d
022			_a0258-851X
024			_a10.21873/invivo.11519 [doi]
024			_a33/2/621 [pii]
040			_aOvid MEDLINE(R)
099			_a30804150
245			_aPerioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience.
251			_aIn Vivo. 33(2):621-626, 2019 Mar-Apr.
252			_aIn Vivo. 33(2):621-626, 2019 Mar-Apr.
253			_aIn vivo (Athens, Greece)
260			_c2019
260			_fFY2019
265			_sppublish
266			_d2019-03-14
520			_aAIM: To present the experience of the upper Gastrointestinal Unit of the Surgical Department of National and Kapodistrian University of Athens in order to inform surgeons of the exact harms and benefits associated with their decisions concerning management of antiplatelet therapy.
520			_aCONCLUSION: It is a reasonable approach to discontinue antiplatelet therapy for more than 7 days before surgery, especially in such a population of patients with esophageal cancer that require complex operations with high bleeding risk.
520			_aCopyright(c) 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
520			_aMATERIALS AND METHODS: This was a single-center study of patients who underwent surgery for esophageal cancer and had concomitant coronary artery disease from 1/1/2005 to 31/7/2017. Patients were divided into two cohorts based on when their antiplatelet therapy was stopped (<7 vs. >=7 days). Esophageal cancer was classified as esophageal only or as Siewert type I, II, or III based on tumor location at the gastroesophageal junction. A univariate logistic regression model was developed to assess the relationship between baseline variables and myocardial infraction, mortality, bleeding and stroke after the operation. For all tests, differences with a value of p<0.05 were considered significant.
520			_aRESULTS: During the study period, 135 esophagectomies were performed for esophageal cancer. Almost 17% of them had concomitant coronary artery disease medically managed with antiplatelet therapy. No difference was found in terms of myocardial infarction, stroke or severe bleeding events between patients that stopped antiplatelet therapy for more or less than 7 days before esophagectomy.
546			_aEnglish
650			_a*Coronary Artery Disease/dt [Drug Therapy]
650			_a*Esophageal Neoplasms/dt [Drug Therapy]
650			_a*Esophageal Neoplasms/su [Surgery]
650			_a*Platelet Aggregation Inhibitors/ad [Administration & Dosage]
650			_aAged
650			_aClopidogrel/ad [Administration & Dosage]
650			_aCoronary Artery Disease/co [Complications]
650			_aCoronary Artery Disease/pp [Physiopathology]
650			_aEsophageal Neoplasms/co [Complications]
650			_aEsophageal Neoplasms/pp [Physiopathology]
650			_aFemale
650			_aHemorrhage/pp [Physiopathology]
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aPerioperative Care
650			_aPlatelet Aggregation Inhibitors/ae [Adverse Effects]
650			_aRisk Assessment
650			_aRisk Factors
650			_aStents/ae [Adverse Effects]
650			_aTiclopidine/ad [Administration & Dosage]
650			_aTiclopidine/ae [Adverse Effects]
651			_aMedStar Washington Hospital Centerumar
656			_aMedicine/General Internal Medicine
657			_aJournal Article
700			_aJonnalagadda, Anil K
790			_aBakopoulos A, Domi V, Jonnalagadda AK, Kapelouzou A, Kokkinidis DG, Liakakos T, Mpaili E, Schizas D, Theochari CA, Theochari NA
856			_uhttps://dx.doi.org/10.21873/invivo.11519 _zhttps://dx.doi.org/10.21873/invivo.11519
942			_cART _dArticle
999			_c4117 _d4117